Plus, news about Talus Bioscience, Moleculin, Organon and Eli Lilly:
Kymera Therapeutics aims to raise $225M: The public offering will be …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The study uncovers factors influencing mpox severity and duration, emphasizing the role of viral load and specific clinical presentations in patient outcomes.
Changes in skull and brain size, as well as the thickness of the cortex, across individuals born between the years 1930 and 1970.
Editor’s note: A recording of the event is embedded below. Pharmacy benefit managers are intermediaries that are supposed to negotiate lower drug costs. But does